Johnson & Johnson's worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients' claims that J&J talc product...

Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss biotech, weight-loss drugs and her playbook.

Johnson & Johnson (NYSE:JNJ) said Tuesday that it expects its 2024 operation sales growth to grow between 5% and 6% as its psoriasis drug Stelara faces competition in the United States. Ahead of a ...

Johnson & Johnson   (NYSE:JNJ) is in focus this morning, after the pharma giant offered up its guidance for 2024 and beyond.

FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.

Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stel...

Johnson & Johnson demonstrates better R&D efficiency and has a larger patent portfolio compared to Pfizer. JNJ's product pipeline in the Pharmaceutical segment has more late-stage developments, sup...

Warren Buffett - known for making successful investments in Dividend Kings over the years - recently sold two popular Dividend Kings. We look at why he may have made these sales. We also share a di...

Shares are lower this year, thanks to an ongoing legal situation, but UBS says those worries are factored into the stock.

CNBC's Jim Cramer explains why he is keeping an eye on shares of Johnson & Johnson.

As a Dividend King with six decades of dividend growth to its credit and a AAA credit rating from S&P, Johnson & Johnson stands in a league of its own. The healthcare behemoth reported solid sales ...

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.11, denoting a +0.32% change from the preceding trading day.

Under current market conditions, our view is that playing defensive is more important than pursuing growth. Against this overall backdrop, this article explains why Johnson & Johnson is a good defe...

U.S. stock market indexes are coming off of four positive weeks, but some top dividend stocks haven't kept pace. Johnson & Johnson stock is trading near a 52-week low despite strong growth from its...

There are few investors who have their every move followed and analyzed like Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) chairman and CEO Warren Buffett. That's because none have the sustained,...